Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports on corporate actions taken at the Special General Meeting of Shareholders held on February 16, 2016. Redhill Biopharma Ltd. is a foreign private issuer based in Tel Aviv, Israel, filing under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Board Composition: Ms. Nurit Benjamini was elected as an external director for a three-year term.
- Capital Structure: The authorized share capital was increased from NIS 2,000,000 (200,000,000 Ordinary Shares) to NIS 3,000,000 (300,000,000 Ordinary Shares). The par value remains NIS 0.01 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves to disclose the shareholder resolutions and incorporates the report by reference into existing Registration Statements (Form S-8 and Form F-3).
Investor Verification Checklist
- Verify the effective date of the increased authorized share capital.
- Confirm the background and qualifications of the newly elected external director, Ms. Nurit Benjamini.
- Review the referenced Registration Statements (Nos. 333-188286, 333-207654, and 333-193503) for details on how the increased capital may be utilized.